UK-listed PureTech Health (LSE: PRTC) today announced that its independent affiliate Akili has entered into a strategic partnership with Japan’s Shionogi (TYO: 4507) for the commercialization of two of Akili’s digital medicine product candidates, AKL-T01 and AKL-T02, in Japan and Taiwan.
AKL-T01 is currently under review with the US Food and Drug Administration as a potential digital treatment for children with attention-deficit/hyperactivity disorder (ADHD), and AKL-T02 is in late-stage development as a potential digital treatment for cognitive function and related symptoms in children with Autism Spectrum Disorder (ASD).
Financial terms of the collaboration
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze